查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631234

CGRP抑制剂的全球市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2032年)

CGRP Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 213 Pages | 商品交期: 2-5个工作天内

价格
简介目录

由于全球偏头痛盛行率不断上升，全球 CGRP 抑制剂市场规模的需求正在激增。这些抑制剂是突破性的药物，针对的是降钙素基因相关胜肽 (CGRP)，这是偏头痛发展的关键治疗标靶。透过抑制 CGRP 的活性，它可以显着降低偏头痛的发作频率和严重程度。预计复合年增长率 (CAGR) 为 13.90%，该市场预计将实现大幅增长，提供有针对性的有效解决方案，重塑偏头痛管理并改善全球数百万人的生活品质。

CGRP 抑制剂透过调节降钙素基因相关胜肽 (CGRP) 的活性发挥作用，降钙素基因相关胜肽是一种在偏头痛发病机制中发挥重要作用的神经肽。透过阻止 CGRP 与其受体结合或抑制其释放，这些抑制剂可显着降低偏头痛的频率和严重程度。作为慢性偏头痛的预防治疗，CGRP 抑制剂正在重塑这种使人衰弱的疾病的治疗分析。

受偏头痛药物的进步以及患者和医疗保健提供者认识的提高的推动，CGRP 抑制剂的全球市场预计将出现显着增长。凭藉创新的解决方案和策略合作伙伴关係，市场参与者能够很好地满足对有效偏头痛治疗日益增长的需求。随着认识的不断深入，CGRP 抑制剂不断重新定义偏头痛管理的标准，为全球数百万人带来希望和生活品质的改善。

全球偏头痛的增加使得需要有针对性的治疗干预，从而推动了对 CGRP 抑制剂的需求。与传统治疗方法相比，CGRP抑制剂的标靶机制具有较高的疗效和良好的安全性，因此增加了其采用率。 CGRP抑制剂的出现凸显了偏头痛治疗的典范转移，强调精准和个人化医疗。医疗保健提供者越来越多地支持预防性偏头痛治疗，因为他们认识到其对患者的长期益处并减少对止痛药的依赖。宣传活动和教育措施在向患者介绍先进的偏头痛治疗方案方面发挥关键作用，进一步推动了对 CGRP 抑制剂的需求。

本报告提供全球CGRP抑制剂市场相关调查，提供市场概要，以及各分子，不同治疗，各给药途径，各最终用途，及各地区趋势，及市场参与市场企业的竞争趋势等资讯。

目录

第1章 摘要整理

第2章 市场概要

  • 市场定义和市场区隔
  • 市场动态
  • 价值链分析
  • 波特的五力分析
  • COVID-19影响分析
  • 乌克兰·俄罗斯纠纷的影响
  • 经济概要
  • 大环境分析

第3章 产量与贸易统计，2019年～2023年

第4章 价格分析，2019年～2023年

第5章 全球CGRP抑制剂市场预测，2019年～2032年

  • 全球CGRP抑制剂市场预测，各分子，金额(10亿美元)，数量(100万个)，2019年～2032年
  • 全球CGRP抑制剂市场预测，不同治疗，金额(10亿美元)，数量(100万个)，2019年～2032年
  • 全球CGRP抑制剂市场预测，各给药途径，金额(10亿美元)，数量(100万个)，2019年～2032年
  • 全球CGRP抑制剂市场预测，各最终用途，金额(10亿美元)，数量(100万个)，2019年～2032年
  • 全球CGRP抑制剂市场预测，各地区，金额(10亿美元)，数量(100万个)，2019年～2032年

第6章 北美的CGRP抑制剂市场预测，2019年～2032年

第7章 欧洲的CGRP抑制剂市场预测，2019年～2032年

第8章 亚太地区的CGRP抑制剂市场预测，2019年～2032年

第9章 南美的CGRP抑制剂市场预测，2019年～2032年

第10章 中东·非洲的CGRP抑制剂市场预测，2019年～2032年

第11章 竞争情形

  • 各给药途径和不同治疗热图
  • 各製造厂商和不同治疗热图
  • 企业市场占有率分析，2022年
  • 竞争仪表板
  • 企业简介
    • Amgen
    • Novartis
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly
    • Lundbeck
    • Abbvie
    • Allergan

第12章 附录

简介目录

The global CGRP inhibitors market is experiencing a surge in demand due to the rising prevalence of migraines worldwide. These inhibitors, a groundbreaking class of pharmaceuticals, target the calcitonin gene-related peptide (CGRP), a key player in migraine development. By preventing CGRP activity, they significantly reduce the frequency and severity of migraines. With a projected compound annual growth rate (CAGR) of 13.90%, the market is poised to achieve substantial growth, offering targeted and effective solutions that are reshaping migraine management and improving the quality of life for millions globally.

Market Insights

CGRP inhibitors work by modulating the activity of the calcitonin gene-related peptide (CGRP), a neuropeptide that plays a significant role in migraine pathogenesis. By preventing CGRP from binding to its receptors or blocking its release, these inhibitors significantly reduce migraine frequency and severity. As preventive treatments for chronic migraines, CGRP inhibitors are reshaping the therapeutic Analysis for this debilitating condition.

The global CGRP inhibitors market is set to witness significant growth, driven by advancements in migraine therapeutics and increasing awareness among patients and healthcare providers. With innovative solutions and strategic collaborations, the market players are well-positioned to address the growing demand for effective migraine treatments. As the Analysis evolves, CGRP inhibitors continue to redefine the standards of care in migraine management, offering hope and improved quality of life for millions worldwide.

Key Market Drivers

  • Rising Migraine Prevalence: The growing global burden of migraines necessitates targeted therapeutic interventions, driving the demand for CGRP inhibitors.
  • Effectiveness and Precision: The targeted mechanism of CGRP inhibitors offers higher efficacy and better safety profiles compared to traditional treatments, increasing their adoption.
  • Advancements in Migraine Care: The emergence of CGRP inhibitors underscores a paradigm shift in migraine therapeutics, emphasizing precision medicine and personalized care.
  • Shifting Treatment Paradigms: Healthcare providers are increasingly favoring preventive migraine treatments, recognizing their long-term benefits for patients and reducing reliance on pain-relief medications.
  • Growing Awareness Among Patients: Awareness campaigns and educational initiatives have played a pivotal role in informing patients about advanced migraine treatment options, further driving demand for CGRP inhibitors.

Business Opportunities

  • Combination Therapies: Exploring combination treatments involving CGRP inhibitors and other migraine management modalities presents a promising avenue for innovation and revenue growth.
  • Strategic Partnerships: Collaborations between pharmaceutical companies, healthcare institutions, and research organizations can enhance awareness, accessibility, and affordability of CGRP inhibitors.
  • Patient-Centric Solutions: Developing non-invasive and patient-friendly delivery methods, such as nasal sprays, can further expand the market reach.

Regional Analysis

  • Europe: As the leading region, Europe is driving market growth through strategic healthcare initiatives, a robust regulatory framework, and a strong focus on advanced migraine therapies.
  • South Asia & Pacific: This region is the fastest-growing market, supported by a rising migraine burden, increased awareness of innovative treatments, and improved healthcare access.
  • North America: The region's advanced healthcare infrastructure and high adoption rates for innovative therapies position it as a critical market for CGRP inhibitors.

Key Players

Prominent companies in the CGRP inhibitors market include:

  • Amgen
  • Novartis
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly
  • Lundbeck
  • Abbvie
  • Allergan

These organizations are at the forefront of research and development, introducing innovative therapies and expanding their product portfolios to maintain a competitive edge.

Market Segmentation

1. By Molecule:

    Small Molecule Large Molecule

2. By Treatment:

    Preventive Migraine Treatment Acute Migraine Treatment

3. By Route of Administration:

    Oral Nasal Injectables

4. By End-Use:

    Hospitals Specialty Clinics Mail Order Pharmacies Retail Pharmacies

5. By Region:

    North America Europe Asia Pacific Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global CGRP Inhibitors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Volume and Value, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact Of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. Pestle Analysis

3. Production Output and Trade Statistics, 2019 - 2023

  • 3.1. Global CGRP Inhibitors Market Production Output, by Region, Value (US$ Bn) and Volume (Million Units),2019 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2019 - 2023

  • 4.1. Global Average Price Analysis, by Type, US$ Per Unit, 2019 - 2023
  • 4.2. Prominent Factor Affecting CGRP Inhibitors Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit, 2019 - 2023

5. Global CGRP Inhibitors Market Outlook, 2019 - 2032

  • 5.1. Global CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Small Molecule
      • 5.1.1.2. Large Molecule
  • 5.2. Global CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Preventive Migraine Treatment
      • 5.2.1.2. Acute Migraine Treatment
  • 5.3. Global CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Nasal
      • 5.3.1.3. Injectables
  • 5.4. Global CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Specialty Clinics
      • 5.4.1.3. Mail Order Pharmacies
      • 5.4.1.4. Retail Pharmacies
  • 5.5. Global CGRP Inhibitors Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 6.1. North America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Small Molecule
      • 6.1.1.2. Large Molecule
  • 6.2. North America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Preventive Migraine Treatment
      • 6.2.1.2. Acute Migraine Treatment
  • 6.3. North America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Nasal
      • 6.3.1.3. Injectables
  • 6.4. North America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Specialty Clinics
      • 6.4.1.3. Mail Order Pharmacies
      • 6.4.1.4. Retail Pharmacies
  • 6.5. North America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.2. U.S. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.3. U.S. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.4. U.S. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.5. Canada CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.6. Canada CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.7. Canada CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.8. Canada CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe CGRP Inhibitors Market Outlook, 2019 - 2032

  • 7.1. Europe CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Small Molecule
      • 7.1.1.2. Large Molecule
  • 7.2. Europe CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Preventive Migraine Treatment
      • 7.2.1.2. Acute Migraine Treatment
  • 7.3. Europe CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Nasal
      • 7.3.1.3. Injectables
  • 7.4. Europe CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Specialty Clinics
      • 7.4.1.3. Mail Order Pharmacies
      • 7.4.1.4. Retail Pharmacies
  • 7.5. Europe CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.2. Germany CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.3. Germany CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.4. Germany CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.5. U.K. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.6. U.K. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.7. U.K. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.8. U.K. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.9. France CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.10. France CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.11. France CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.12. France CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.13. Italy CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.14. Italy CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.15. Italy CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.16. Italy CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.17. Turkey CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.18. Turkey CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.19. Turkey CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.20. Turkey CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.21. Russia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.22. Russia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.23. Russia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.24. Russia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.25. Rest Of Europe CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.26. Rest Of Europe CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.27. Rest Of Europe CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.28. Rest of Europe CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific CGRP Inhibitors Market Outlook, 2019 - 2032

  • 8.1. Asia Pacific CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Small Molecule
      • 8.1.1.2. Large Molecule
  • 8.2. Asia Pacific CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Preventive Migraine Treatment
      • 8.2.1.2. Acute Migraine Treatment
  • 8.3. Asia Pacific CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Nasal
      • 8.3.1.3. Injectables
  • 8.4. Asia Pacific CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Specialty Clinics
      • 8.4.1.3. Mail Order Pharmacies
      • 8.4.1.4. Retail Pharmacies
  • 8.5. Asia Pacific CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. China CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.2. China CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.3. China CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.4. China CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.5. Japan CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.6. Japan CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.7. Japan CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.8. Japan CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.9. South Korea CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.10. South Korea CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.11. South Korea CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.12. South Korea CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.13. India CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.14. India CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.15. India CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.16. India CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.17. Southeast Asia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.18. Southeast Asia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.19. Southeast Asia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.20. Southeast Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.21. Rest Of Asia Pacific CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.22. Rest Of Asia Pacific CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.23. Rest Of Asia Pacific CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.24. Rest of Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 9.1. Latin America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Small Molecule
      • 9.1.1.2. Large Molecule
  • 9.2. Latin America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Preventive Migraine Treatment
      • 9.2.1.2. Acute Migraine Treatment
  • 9.3. Latin America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oral
      • 9.3.1.2. Nasal
      • 9.3.1.3. Injectables
  • 9.4. Latin America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospitals
      • 9.4.1.2. Specialty Clinics
      • 9.4.1.3. Mail Order Pharmacies
      • 9.4.1.4. Retail Pharmacies
  • 9.5. Latin America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.2. Brazil CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.3. Brazil CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.4. Brazil CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.5. Mexico CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.6. Mexico CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.7. Mexico CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.8. Mexico CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.9. Argentina CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.10. Argentina CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.11. Argentina CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.12. Argentina CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.13. Rest Of Latin America CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.14. Rest Of Latin America CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.15. Rest Of Latin America CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.16. Rest of Latin America CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa CGRP Inhibitors Market Outlook, 2019 - 2032

  • 10.1. Middle East & Africa CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.1.1. Key Highlights
      • 10.1.1.1. Small Molecule
      • 10.1.1.2. Large Molecule
  • 10.2. Middle East & Africa CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.2.1. Key Highlights
      • 10.2.1.1. Preventive Migraine Treatment
      • 10.2.1.2. Acute Migraine Treatment
  • 10.3. Middle East & Africa CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.3.1. Key Highlights
      • 10.3.1.1. Oral
      • 10.3.1.2. Nasal
      • 10.3.1.3. Injectables
  • 10.4. Middle East & Africa CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.4.1. Key Highlights
      • 10.4.1.1. Hospitals
      • 10.4.1.2. Specialty Clinics
      • 10.4.1.3. Mail Order Pharmacies
      • 10.4.1.4. Retail Pharmacies
  • 10.5. Middle East & Africa CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.2. GCC CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.3. GCC CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.4. GCC CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.5. South Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.6. South Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.7. South Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.8. South Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.9. Egypt CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.10. Egypt CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.11. Egypt CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.12. Egypt CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.13. Nigeria CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.14. Nigeria CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.15. Nigeria CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.16. Nigeria CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.17. Rest Of Middle East & Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.18. Rest Of Middle East & Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.19. Rest Of Middle East & Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.20. Rest of Middle East & Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. By Route of Administration Vs by Treatment Heat Map
  • 11.2. Manufacturer Vs by Treatment Heatmap
  • 11.3. Company Market Share Analysis, 2022
  • 11.4. Competitive Dashboard
  • 11.5. Company Profiles
    • 11.5.1. Amgen
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Type Portfolio
      • 11.5.1.3. Financial Overview
      • 11.5.1.4. Business Strategies and Development
    • 11.5.2. Novartis
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Type Portfolio
      • 11.5.2.3. Financial Overview
      • 11.5.2.4. Business Strategies and Development
    • 11.5.3. Teva Pharmaceutical Industries Ltd.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Type Portfolio
      • 11.5.3.3. Financial Overview
      • 11.5.3.4. Business Strategies and Development
    • 11.5.4. Eli Lilly
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Type Portfolio
      • 11.5.4.3. Financial Overview
      • 11.5.4.4. Business Strategies and Development
    • 11.5.5. Lundbeck
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Type Portfolio
      • 11.5.5.3. Financial Overview
      • 11.5.5.4. Business Strategies and Development
    • 11.5.6. Abbvie
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Type Portfolio
      • 11.5.6.3. Financial Overview
      • 11.5.6.4. Business Strategies and Development
    • 11.5.7. Allergan
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Type Portfolio
      • 11.5.7.3. Financial Overview
      • 11.5.7.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms And Abbreviations